Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients

Cancer Research

Volumn 63, Issue 8, 2003, Pages 1806-1813

  Bellnier, David A ^a   Greco, William R ^a   Loewen, Gregory M ^a   Nava, Hector ^a   Oseroff, Allan R ^a   Pandey, Ravindra K ^a   Tsuchida, Takaaki ^b   Dougherty, Thomas J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 HEXYLOXYETHYL) 2 DEVINYLPYROPHEOPHORBIDE A; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BARRETT ESOPHAGUS; BASAL CELL CARCINOMA; BLOOD LEVEL; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INFUSION; DRUG LIVER LEVEL; DRUG MEGADOSE; DYSPLASIA; ESOPHAGUS CARCINOMA; EXPERIMENTAL MODEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIGHT; LIVER MICROSOME; LOW DRUG DOSE; LUNG CARCINOMA; MALE; NONLINEAR REGRESSION ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE; SKIN TOXICITY; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BLOOD PROTEINS; CARCINOMA, BASAL CELL; CHLOROPHYLL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; ESOPHAGEAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN; SKIN NEOPLASMS;

EID: 0345269101     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dougherty, T. J. An update on photodynamic therapy applications. J. Clin. Laser Med. Surg., 20: 3-7, 2002.
2. Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., et al. Photodynamic therapy. J. Natl. Cancer Inst. (Bethesda), 90: 889-905, 1998.
3. Lee, L. K., Whitehurst, C., Pantelides, M. L., and Moore, J. V. In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland. Photochem. Photobiol., 62: 882-886, 1995.
4. Moriwaki, S. I., Misawa, J., Yoshinari, Y., Yamada, I., Takigawa, M., and Tokura, Y. Analysis of photosensitivity in Japanese cancer-bearing patients receiving photodynamic therapy with porfimer sodium (Photofrin). Photoderm. Photoimmunol. Photomed., 17: 241-243, 2001.
5. Kessel, D., and Dougherty, T. J. Agents used in photodynamic therapy. Rev. Contemp. Pharmacother., 10: 19-24, 1999.
6. Pandey, R. K., Bellnier, D. A., Smith, K. M., and Dougherty, T. J. Chlorin and porphyrin derivatives as potential photosensitizers in photodynamic therapy. Photochem. Photobiol., 53: 65-72, 1991.
7. Henderson, B. W., Bellnier, D. A., Greco, W. R., Sharma, A., Pandey, R. K., Vaughan, L. A., et al. An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res., 57: 4000-4007, 1997.
8. Payne, J. T., McCaw, D. L., Casteel, S. W., Frazier, D., Rogers, K., and Tompson, R. V. Pharmacokinetics of pyropheophorbide-a-hexyl ether in the dog. Lasers Surg. Med., 18: 406-409, 1996.
9. Bellnier, D. A., Henderson, B. W., Pandey, R. K., Potter, W. R., and Dougherty, T. J. Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a. J. Photochem. Photobiol. B Biol., 20: 55-61, 1993.
10. Bellnier, D. A., Greco, W. R., Parsons, J. C., Oseroff, A. R., Kuebler, A., and Dougherty, T. J. An assay for the quantitation of Photofrin in tissues and fluids. Photochem. Photobiol., 66: 237-244, 1997.
11. Woodburn, K., and Kessel, D. Effect of density-gradients on the binding of photosensitizing agents to plasma proteins. Int. J. Biochem. Cell Biol., 27: 499-506, 1995.
12. Jusko, W. J. Guidelines for collection and analysis of pharmacokinetic data. In: W. E. Evans, J. J. Schentag, and W. J. Jusko, (eds.), Applied Pharmacokinetics, 3rd ed., pp. 2-1-2-43. Vancouver, WA: Applied Therapeutics Inc., 1992.
13. Loo, T. L., and Riegelman, S. Assessment of pharmacokinetic constants from post infusion blood curves obtained after IV infusion. J. Pharm. Sci., 59: 53-55, 1970.
14. SAS Institute Inc. The NLIN Procedure. In: SAS/STAT User's Guide. Version 8, Vol. 2, pp. 2371-2418. Cary, NC: SAS Institute Inc., 1999.
15. SAS Institute Inc. The NLMIXED Procedure. In: SAS/STAT User's Guide, Version 8, Vol. 2, pp. 2419-2504. Cary, NC: SAS Institute Inc., 1999.
16. Pandey, R. K., Sumlin, A. B., Constantine, S., Aoudia, M., Potter, W. R., Bellnier, D. A., et al. Alkyl ether analogs of chlorophyll-a derivatives. I. Synthesis, photophysical properties and photodynamic efficacy. Photochem. Photobiol., 64: 194-204, 1996.
17. Bellnier, D. A., and Dougherty, T. J. A preliminary pharmacokinetic study of intravenous Photofrin in patients. J. Clin. Laser Med. Surg., 14: 311-314, 1996.
18. Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., and Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep., 50: 219-244, 1966.
19. Gibaldi, M., and McNamara, P. J. Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur. J. Clin. Pharmacol., 13: 373-378, 1978.
20. MacKichan, J. J. Influence of protein binding and use of unbound (free) drug concentrations. In: W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics. 3rd ed., pp. 5-1-5-48. Vancouver, WA: Applied Therapeutics Inc., 1992.
21. Dougherty, T. J., Pandey, R. K. Nava, H. R., Smith, J. A., Douglass, H. O., Edge, S. B., et al. Preliminary clinical data on a new photodynamic therapy photosensitizer, 2-[1-hexyloxyethyll-2-devinylpyropheophorbide-a (HPPH), for treatment of obstructive esophageal cancer. In: T. J. Dougherty (ed.), Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy, Vol. 3909, pp. 25-27. Bellingham, WA: SPIE Press, 2000.
22. Tomio, L., Zorat, P. L., Jori, G., Reddi, E., Salvato, C., et al. Elimination pathway of hematoporphyrin from normal and tumor-bearing rats. Tumori, 68: 283-286, 1982.
23. Cai, H., Wang, Q., Luo, J., and Lim, C. K. Study of temoporfin metabolism by HPLC and electrospray mass spectrometry. Biomed. Chromatogr., 13: 354-359, 1999.
24. Bellnier, D. A., Ho, Y-K., Pandey, R. K., Missert, J. R., and Dougherty, T. J. Distribution and elimination of Photofrin II in mice. Photochem. Photobiol., 50: 221-228, 1989.
25. United States Department of HHS, FDA, CDER, CBER. Guidance for Industry Population Pharmacokinetics. pp. 1-31. Rockville, MD; Office of Training and Communications, Division of Communications Management, 1999.